Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo

Leukemia Research

Volumn 27, Issue 12, 2003, Pages 1105-1108

  Demir, Gokhan ^a   Klein, Hans Otto ^b   Tuzuner, Nukhet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Dendritic cells; Fas Apo 1; GM CSF; Malignant melanoma; Monocytes

Indexed keywords

CD45 ANTIGEN; FAS ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; CELL ACTIVATION; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MALE; MELANOMA; MONOCYTE; MYALGIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT;

EID: 0042164627     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00097-3     Document Type: Article

References (9)

1. Glaspy JA. Colony-stimulating factors in oncology. Principles and practice of the biologic therapy of cancer. In: Rosenberg SA, editor. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 141-52.
2. Daro E., Butz E., Smith J., Teepe M., Maliszewski C.R., McKenna H.J. Comparison of the functional properties of murine dendritic cells generated in vivo with Flt3 ligand GM-CSF and Flt3 ligand plus GM-CSF. Cytokine. 17(3):2002;119-130.
3. Daro E., Pulendran B., Brasel K., Teepe M.et al. Polyethylene glycol-modified GM-CSF expands CD11b (high) CD11c (high) but not CD11b (low) CD11c (high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J. Immunol. 165(1):2000;49-58.
4. Galati G., Rovere P., Citterio G., Bondanza A., Scagliette U., Bucci E.et al. In vivo administration of GM-CSF promotes the clearance of apoptotic cells: effects on monocytes and polymorphonuclear leukocytes. J. Leukoc. Biol. 67(2):2000;174-182.
5. Heystek H.C., Mudde G.C., Ohler R., Kalthoff F.S. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone. Clin. Exp. Immunol. 120(3):2000;440-447.
6. Demir G., Ozguroglu M., Sayhan N., Molinas-Mandel N., Demirelli F., Buyukunal E.et al. Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (Apo-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study). Anticancer Res. 19(4C):1999;3517-3520.
7. Ashany D., Song X., Lacy E., Nikolic-Zugic J., Friedman S.M., Elkon K.B. Th1 CD4+ lymphocytes delete activated macrophages through the Fas/Apo-1 antigen pathway. Proc. Natl. Acad. Sci. U.S.A. 92(24):1995;11225-11229.
8. Kedzierska K., Rainbird M.A., Lopez A.F., Crowe S.M. Effect of GM-CSF on HIV-1 replication in monocytes/macrophages in vivo and in vitro: a review. Vet. Immunol. Immunopathol. 63(1-2):1998;111-121.
9. Robinson S.P., Patterson S., English N., Davies D., Knight S.C., Reid C.D. Human periphreal blood contains two distinct linages of dendritic cells. Eur. J. Immunol. 29(9):1999;2769-2778.